The toll-like receptor 3 Ligand, Poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143

Stem Cells

Volumn 32, Issue 2, 2014, Pages 521-533

  Zhao, Xiaoyin ^a   Liu, Dan ^a   Gong, Wei ^a   Zhao, Guangfeng ^a   Liu, Liu ^a   Yang, Liu ^a   Hou, Yayi ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Mesenchymal stem cells; MiR 143; Sepsis; Toll like receptor 3

Indexed keywords

MESENCHYMAL STEM CELLS; MIR-143; SEPSIS; TOLL-LIKE RECEPTOR 3;

CELL DIFFERENTIATION; CYCLOOXYGENASE 2; HUMANS; IMMUNOSUPPRESSION; MACROPHAGES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICRORNAS; POLY I-C; RNA, MESSENGER; SEPSIS; TOLL-LIKE RECEPTOR 3; UMBILICAL CORD;

EID: 84894521405     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1543     Document Type: Article

References (70)

1. Karahuseyinoglu S, Cinar O, Kilic E et al. Biology of stem cells in human umbilical cord stroma: In situ and in vitro surveys. Stem Cells 2007;25: 319-331.
2. Liu L, Zhao X, Li P et al. A novel way to isolate MSCs from umbilical cords. Eur J Immunol 2012;42: 2190-2193.
3. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31: 890-896.
4. Le Blanc K, Tammik L, Sundberg B et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57: 11-20.
5. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105: 1815-1822.
6. Benvenuto F, Ferrari S, Gerdoni E et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 2007;25: 1753-1760.
7. Crop MJ, Baan CC, Korevaar SS et al. Human adipose tissue-derived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev 2010;19: 1843-1853.
8. Parekkadan B, Tilles AW, Yarmush ML. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 2008;26: 1913-1919.
9. Tabera S, Perez-Simon JA, Diez-Campelo M et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008;93: 1301-1309.
10. Asari S, Itakura S, Ferreri K et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol 2009; 37: 604-615.
11. Spaggiari GM, Capobianco A, Abdelrazik H et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008;111: 1327-1333.
12. Giuliani M, Oudrhiri N, Noman ZM et al. Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood 2011;118: 3254-3262.
13. Spaggiari GM, Abdelrazik H, Becchetti F et al. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009;113: 6576-6583.
14. Jiang XX, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005;105: 4120-4126.
15. Zhang Q, Shi S, Liu Y et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009;183: 7787-7798.
16. Sun L, Wang D, Liang J et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010;62: 2467-2475.
17. Sun L, Akiyama K, Zhang H et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009;27: 1421-1432.
18. Lombardo E, DelaRosa O, Mancheno-Corvo P et al. Toll-like receptor-mediated signaling in human adipose-derived stem cells: Implications for immunogenicity and immunosuppressive potential. Tissue Eng Part A 2009;15: 1579-1589.
19. Opitz CA, Litzenburger UM, Lutz C et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009;27: 909-919.
20. Liotta F, Angeli R, Cosmi L et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008;26: 279-289.
21. Yamamoto-Furusho JK, Podolsky DK. Innate immunity in inflammatory bowel disease. World J Gastroenterol 2007;13: 5577-5580.
22. Ishihara S, Rumi MA, Ortega-Cava CF et al. Therapeutic targeting of toll-like receptors in gastrointestinal inflammation. Curr Pharm Des 2006;12: 4215-4228.
23. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29: 1303-1310.
24. Danchuk S, Ylostalo JH, Hossain F et al. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-alpha-induced protein 6. Stem Cell Res Ther 2011;2: 27.
25. Gupta N, Su X, Popov B et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007;179: 1855-1863.
26. Gupta N, Krasnodembskaya A, Kapetanaki M et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012;67: 533-539.
27. Krasnodembskaya A, Song Y, Fang X et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010;28: 2229-2238.
28. Lee JW, Fang X, Gupta N et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA 2009;106: 16357-16362.
29. Mei SH, McCarter SD, Deng Y et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. Plos Med 2007;4: e269.
30. Nemeth K, Leelahavanichkul A, Yuen PS et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15: 42-49.
31. Gonzalez-Rey E, Anderson P, Gonzalez MA et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009;58: 929-939.
32. Mei SH, Haitsma JJ, Dos Santos CC et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010;182: 1047-1057.
33. Bochud PY, Calandra T. Pathogenesis of sepsis: New concepts and implications for future treatment. BMJ 2003;326: 262-266.
34. Zhao X, Liu L, Liu D et al. Progesterone enhances immunoregulatory activity of human mesenchymal stem cells via PGE2 and IL-6. Am J Reprod Immunol 2012;68: 290-300.
35. Hu YL, Li PF, Hao S et al. Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia. Clin Chem Lab Med 2009;47: 923-929.
36. Zhao X, Liu L, Liu D et al. Progesterone Enhances Immunoregulatory Activity of Human Mesenchymal Stem Cells Via PGE2 and IL-6. Am J Reprod Immunol. 2012.
37. Rittirsch D, Huber-Lang MS, Flierl MA et al. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 2009;4: 31-36.
38. Pevsner-Fischer M, Morad V, Cohen-Sfady M et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007;109: 1422-1432.
39. Tomchuck SL, Zwezdaryk KJ, Coffelt SB et al. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008;26: 99-107.
40. Yu S, Cho HH, Joo HJ et al. Role of MyD88 in TLR agonist-induced functional alterations of human adipose tissue-derived mesenchymal stem cells. Mol Cell Biochem 2008;317: 143-150.
41. van den Berk LC, Jansen BJ, Siebers-Vermeulen KG et al. Toll-like receptor triggering in cord blood mesenchymal stem cells. J Cell Mol Med 2009;13: 3415-3426.
42. Waterman RS, Tomchuck SL, Henkle SL et al. A new mesenchymal stem cell (MSC) paradigm: Polarization into a proinflammatory MSC1 or an Immunosuppressive MSC2 phenotype. Plos One 2010;5: e10088.
43. Mastri M, Shah Z, McLaughlin T et al. Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency. Am J Physiol Cell Physiol 2012;303: C1021-1033.
44. Murakami M, Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res 2004;43: 3-35.
45. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105: 2214-2219.
46. Anastassiou ED, Paliogianni F, Balow JP et al. Prostaglandin E2 and other cyclic AMPelevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. J Immunol 1992;148: 2845-2852.
47. Esaki Y, Li Y, Sakata D et al. Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010;107: 12233-12238.
48. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281: 1191-1193.
49. Nauta AJ, Kruisselbrink AB, Lurvink E et al. Mesenchymal stem cells inhibit generation and function of both CD341-derived and monocyte-derived dendritic cells. J Immunol 2006;177: 2080-2087.
50. Djouad F, Charbonnier LM, Bouffi C et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007;25: 2025-2032.
51. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294: 862-864.
52. Lai EC. Micro RNAs are complementary to 30 UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 2002;30: 363-364.
53. Zhang B, Pan X, Anderson TA. MicroRNA: A new player in stem cells. J Cell Physiol 2006;209: 266-269.
54. Goff LA, Boucher S, Ricupero CL et al. Differentiating human multipotent mesenchymal stromal cells regulate microRNAs: Prediction of microRNA regulation by PDGF during osteogenesis. Exp Hematol 2008;36: 1354-1369.
55. Greco SJ, Rameshwar P. MicroRNAs regulate synthesis of the neurotransmitter substance P in human mesenchymal stem cellderived neuronal cells. Proc Natl Acad Sci USA 2007;104: 15484-15489.
56. Liu L, Wang Y, Fan H et al. Mir-181a regulates MSCs growth and immune function: MicroRNA-181a regulates local immune balance by inhibiting proliferation and immunosuppressive properties of mesenchymal stem cells. Stem Cells. 2012;30: 1756-1770.
57. Sato S, Sugiyama M, Yamamoto M et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANKbinding kinase 1, and activates two distinct transcription factors, NF-kappa B And IFNregulatory factor-3, in the Toll-like receptor signaling. J Immunol 2003;171: 4304-4310.
58. Chen ZJ. Ubiquitin signalling in the NFkappaB pathway. Nat Cell Biol 2005;7: 758-765.
59. Meylan E, Burns K, Hofmann K et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 2004;5: 503-507.
60. Adhikari A, Xu M, Chen ZJ. Ubiquitinmediated activation of TAK1 and IKK. Oncogene 2007;26: 3214-3226.
61. Sato S, Sanjo H, Takeda K et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005;6: 1087-1095.
62. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211: 27-35.
63. Le Blanc K, Ringden O. Mesenchymal stem cells: Properties and role in clinical bone marrow transplantation. Curr Opin Immunol 2006;18: 586-591.
64. Matthay MA. Advances and challenges in translating stem cell therapies for clinical diseases. Transl Res 2010;156: 107-111.
65. Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: Let's not overlook some essential precautions. Blood 2007;109: 3147-3151.
66. Rittirsch D, Hoesel LM, Ward PA. The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 2007;81: 137-143.
67. Remick DG, Newcomb DE, Bolgos GL et al. Comparison of the mortality and inflammatory response of two models of sepsis: Lipopolysaccharide vs. cecal ligation and puncture. Shock 2000;13: 110-116.
68. Deitch EA. Rodent models of intraabdominal infection. Shock 2005;24 (Suppl 1): 19-23.
69. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: Setting the stage. Nat Rev Drug Discov 2005;4: 854-865.
70. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock-A review of laboratory models and a proposal. J Surg Res 1980;29: 189-201.